BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Novartis Pharmaceuticals Corporation 

One Health Plaza

East Hanover  New Jersey  07936-1080  U.S.A.
Phone: 973-781-8300 Fax: 973-781-8265


SEARCH JOBS






Collaborations

Vicuron Pharmaceuticals, Inc.  Deformylase and MUR: Pathway inhibitors for novel mechanism based antimicrobial drugs





 Company News
Relapsing MS Patients More Satisfied With Novartis Pharmaceuticals Corporation (NVS) Oral Drug Gilenya® Than Standard Injectable Therapies, According to New Study Results at Consortium Service Management Group (CTUM.OB) 5/30/2013 6:39:55 AM    More...
New Analysis Shows Novartis Pharmaceuticals Corporation (NVS) Drug Gilenya® Significantly Reduced Rate of Brain Volume Loss Across Three Large Phase III Studies 3/21/2013 10:34:29 AM    More...
Novartis Pharmaceuticals Corporation (NVS) Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy 2/25/2013 10:38:43 AM    More...
The New England Journal of Medicine Published Study Shows Novartis Pharmaceuticals Corporation (NVS) Compound ACZ885 Significantly Relieves Symptoms in Patients With Serious Form of Childhood Arthritis 12/20/2012 8:36:58 AM    More...
Selexys Pharmaceuticals Corporation Completes $23 Million Equity Financing and Signs Agreement With Novartis Pharmaceuticals Corporation (NVS) for Up to $665 Million 9/19/2012 7:29:31 AM    More...
FDA Panel Backs Novartis Pharmaceuticals Corporation (NVS)'s Cystic Fibrosis Drug 9/6/2012 7:20:08 AM    More...
Novartis Pharmaceuticals Corporation (NVS) Drug RAD001 Plus Reduced Tacrolimus Provides Similar Efficacy and Better Renal Function Compared to Standard Tacrolimus, Study Shows 8/10/2012 11:23:54 AM    More...
Two New Analyses Reinforce Consistent Efficacy of Novartis Pharmaceuticals Corporation (NVS) Therapy Gilenya Across Wide Range of Relapsing MS Patients 5/31/2012 2:14:02 PM    More...
TV Host Phil Keoghan and Professional Women Cyclists Join Novartis Pharmaceuticals Corporation (NVS) to Raise Awareness of Multiple Sclerosis 5/8/2012 10:44:28 AM    More...
Novartis Pharmaceuticals Corporation (NVS) Expands Transplant Portfolio With Hecoria®, the First Generic Tacrolimus That Can be Prescribed by Brand Name 4/3/2012 11:12:11 AM    More...
12345678910...